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EDITORIAL
Renal transport proteins in excreted urine: Gold mine
or gold dust?
A decade ago, the Sasaki laboratory from Tokyo
demonstrated the regular occurrence of aquaporin-2
(AQP-2) water channel in excreted urine of patients [1].
Its excretion rate appeared to correlate with the plasma
vasopressin (VP) concentration [1]. In the present issue
of Kidney International, Funayama et al [2] from Saitama
report urinary AQP-2 excretion rates in 65 patients suf-
fering cardiac failure (CF). The authors find increased VP
and increased urinary AQP-2, and they conclude that the
latter depends on the former [2]. Anything new or de´ja
vue?
The present data [2] are intriguing. First, the relation-
ship between AQP-2 and VP turns out to be less straight-
forward than expected. For example, although urinary
AQP-2 and VP were unquestionably related in a general
sense, one detail of the study shows a decrease of AQP-2
when the simultaneous VP increased by approximately
100% (group IV vs. III) (Figs. 1A and 2). Conceivably,
this discrepancy could be due to: the clinical nature of
the New York Heart Association (NYHA) classification;
inherent variations of VP within short periods of time in
a given patient; and the very high VP in the group IV
and III patients alike probably causing near complete V2
receptor occupancy in both. But there may be more rea-
sons. According to the literature [3], it is possible that
the urinary AQP-2 excretion rate is more a reflection of
the actual abundance of AQP-2 in the apical cell mem-
brane of collecting duct principal cells (CD-PC) rather
than one of related VP. This would be interesting. If con-
firmed in patients it would imply that urinary AQP-2 is
a superior measure of actual CD water permeability, and
one that clinicians have at their disposal. Another con-
sideration is that the V2 receptor–mediated signalling is
subject to cellular modification [e.g., 4]. Therefore, mea-
suring “the final common pathway” in the form of uri-
nary AQP-2 may provide more of a close-up picture of
the action than measuring VP. Both aspects of reasoning,
therefore, suggest that more should be done to substan-
tiate (or discredit) this new potential paradigm. Perhaps
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simultaneous measurements of free water clearance, uri-
nary AQP-2 (and VP) could serve towards these ends. At
a time when V2-VP antagonists are hitting the clinician’s
doorstep [5], improved tools in the “water trade” would
seem to be no small fry.
The foregoing speculations bring up a second point:
How does AQP-2 get into the tubular fluid? Very lit-
tle research has been reported. It appears that neither
sloughing of CD cells nor shedding of cell membrane are
involved [1]. Hypothetically, retrieval of AQP-2 from
CD-PC apical membrane into multivesicular bodies
(MVB) may be the mechanism. It could lead to pack-
aging of undegradated AQP-2 into endosomes, followed
by their exocytic fusion with the cell membrane, and
release of undegradated AQP-2 into the tubular fluid
[6, 7], since the endosomal pathway serves to bypass
lysosomes in the case of proteins that are difficult to
degradate [7]. However, there is no specific data directly
reporting AQP-2, MVB, and endosomes. Conceivably,
basic research using cultured cells [e.g., 8] might help to
shed light on these issues. A clear understanding of the
pathway(s) of “transfer” of AQP-2 from cell to tubular
fluid shall be paramount. Why? Because interpretations
of urinary AQP-2 will eventually depend on whether its
“transfer” from cell membrane to urine occurs in some
tightly regulated manner or is chaotic. My bias is that
only in the former scenario will the stake begin to resem-
ble a veritable goldmine, as opposed to a barren land with
some gold dust.
And then there is yet another twist. Knepper et al
from Bethesda, Maryland, published evidence showing
the presence of all major apical renal tubular salt trans-
porters in excreted urine [e.g., 9]. The implicit suggestion
was that if the urinary excretion rates were measured
they would correspond to the transporters’ abundance
in the kidney [10]. The resemblance of this situation—
and its open questions—to our foregoing discussion of
AQP-2 is obvious. Here [9], the goldmine would shine
even more blindingly because of nuggets in there sup-
posedly labelled “Gitelman syndrome,” “protein rescue,”
“ADPKD-I,” “renal transplantation,” etc. However, for
now we must remain with our feet firmly on the ground.
We first have to do the homework. We must clarify the
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mode of “transfer” of apical membrane proteins into the
tubular fluid. The article by Funayama et al [2] in the
present issue of Kidney International is stimulating in sev-
eral ways, including this one. Stay tuned!
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